Objectives: To assess the prevalence of minority resistant variants (MRV) and X4-tropic minority variants in ART-naive HIV-2-infected patients.
Introduction
HIV-2 infection represents a unique model of attenuated retroviral infection characterized by slow disease progression, low viral production with 70% of ART-naive patients displaying a plasma viral load (VL) ,100 copies/mL and a low rate of transmission. [1] [2] [3] [4] Currently, genotypic resistance testing in routine follow-up of HIV-infected patients is performed using Sanger standard technology with a threshold 20% to detect viral variants. 5 In HIV-1 infection the presence of minority resistant variants (MRV) has been evidenced to only impact the virological response to the first-generation NNRTI-based treatment with a 2-3-fold increase of the risk of virological failure to this drug class. 6, 7 No evidence of MRV impact has been shown for second-generation NNRTIs, 8 protease inhibitors 9 and integrase inhibitors. 10 To date, ultra-deep sequencing (UDS) technologies are still reserved for research use without recommendations regarding bioinformatics pipelines for detecting and quantifying MRV.
In HIV-2 infection, some studies conducted in different countries have assessed the prevalence of transmitted drug resistance (TDR) by Sanger technology. [11] [12] [13] However, no data are available on the prevalence of MRV in HIV-2 infection. The aim of this study was to develop UDS technology for several HIV-2 genomic regions to assess the prevalence of MRV and X4-tropic minority variants in ART-naive HIV-2-infected patients.
Patients and methods

Study patients
ART-naive HIV-2-infected patients with detectable plasma VL (i.e. .100 copies/mL) diagnosed between 2011 and 2015 and for whom a plasma sample was available were consecutively enrolled. All patients were included in the Agence Nationale de Recherche sur le SIDA et les hé patites virales (ANRS) CO5 HIV-2 Cohort and written informed consent was obtained from each patient at the time of inclusion in the cohort.
UDS of protease, RT, integrase and gp105 regions
Viral RNA was extracted using the DSP Virus/Pathogene midi kit V R (Qiagen, Hilden, Germany) from 1 mL of plasma. RT, protease, integrase and gp105 regions were amplified by RT-PCR according to the manufacturer's instructions (Titan One Tube RT-PCR Kit; Roche, Mannheim, Germany) using the following primers: RTC/RT2 for RT, DP20/PRRT1for protease, INT1S/INT1AS for integrase and H2GPTITANS/H2GPTITANAS for gp105. [14] [15] [16] Nested-PCR reactions were performed with Q5 Taq High-Fidelity DNA Polymerase V R (New England Biolabs, Ipswich, MA, USA), following the manufacturer's instructions and different sets of primers (Table 1) . Nested PCR conditions consisted of an initial denaturation at 98 C for 2 min, followed by 10 cycles (98 C for 30 s, 55 C for 1 min and 72 C for 45 s) and by 30 cycles (98 C for 30 s, 70 C for 1 min and 72 C for 45 s), and then a final elongation step (72 C for 7 min). Nested PCR products were analysed using HT DNA 5K/RNA LabChip V R (Perkin Elmer, Waltham, MA, USA) with the HT DNA 5K V R kit (Perkin Elmer). Protease, RT, integrase and gp105 amplicons were purified with SPRIselect V R (Beckman Coulter, Pasadena, CA, USA) with 0.65, 0.5, 0.65 and 0.5 ratios, respectively.
The UDS protocol was performed on a GS Junior V R (Roche 454 Life Sciences, Branford, CT, USA) using the emPCR Amplification Method-LibA 
Bioinformatic analysis
Sequences were analysed using the Amplicon Variant Analyzer V R (Roche) and Geneious V R research software (version 9.0.5). Only mutations .1% with a coverage .5000 reads and present in .50 reads were retained. 17 The presence of the MRV was technically validated by the number of reads, its presence in similar proportions in both forward and reverse reads, a quality Phred score .20 and the visual inspection of the read alignment indicated good quality.
Protease, RT and integrase resistance-associated mutations (RAMs) were identified using the HIV-2 ANRS resistance interpretation algorithm (www.hivfrenchresistance.org, September 2016, Version 26). 18 Obviously, polymorphic drug resistance mutations should not be used for surveillance of TDR, because they could lead to falsely elevated estimates of transmitted resistance. To do so, we only retained mutations present in ,10% of sequences issued from ART-naive HIV-2-infected patients among the ANRS list of mutations (GenBank update: 2017-06-16/hiv.lanl.gov). Thus, mutations retained were the following: (i) protease: G48V, I50L/V, I54M/L, V62A, I82F, I84V, L90M; (ii) RT: K65R, D67N, N69S/T, K70N/R, L74V, Y115F, Q151M, M184I/V, S215A/C/F/L/Y, K223R; and (iii) integrase: E92Q, T97A, G140S, Y143C/G/R, Q148K/R, N155H.
Mutational load was calculated by multiplying the percentage of the MRV by the plasma VL value.
For gp105 sequence analyses, 'in-house' software was developed to analyse individually each read for tropism prediction using HIV-2 major determinants of CXCR4 co-receptor use we previously described: L18Z; V19K/R; V3 loop global net charge; insertions at position 24. 16 
Results
Patients' characteristics
Forty-seven patients were enrolled in this study. Median age was 47 years (IQR 36-54), 62% were women, 72% originated from West Africa and 15% had CDC-C disease stage. Median CD4 cell count was 328 cells/mm 3 (IQR 216-428). Median plasma VL was 1967 copies/mL (IQR 718-4188). Sixty-eight per cent of patients were infected with HIV-2 group A and 32% with group B.
Protease, RT and integrase UDS
The rate of amplification was 87% (n " 41/47), 81% (n " 38/47) and 47% (n " 22/47) for protease, RT and integrase regions, respectively. Among amplified samples, UDS allowed us to obtain a median of 8865 reads per nucleotide position (range 6922-13779) for the protease region, of 8878 (range 3582-17739) for RT and of 7942 (range 3053-11059) for integrase.
Three samples displayed a RAM above the 20% detection threshold, all in the RT region [N69S (n " 2) and M184V (n " 1) in proportions of 91.4%, 50.1% and 97.8%, respectively]; resulting in a prevalence of TDR for NRTI drug class of 7.9% (95% CI 0.0-16.5). Of note, the M184V change confers resistance to lamivudine and emtricitabine. No RAM above the 20% detection threshold was been detected in protease and integrase regions.
At the 1% detection threshold, the proportion of RAM detected in seven samples was a median of 1.4% (IQR 1.1%-1.8%) ( Table 2) . Four samples harboured MRV in protease: I50V (n " 3), V47A (n " 1) and I54L (n " 1). Of note, one sample displayed two MRVs, both present on the same viral genomes. The presence of Storto et al.
these PI RAMs was interpreted as resistance to lopinavir (V47A), to darunavir (I50V) and as possible resistance to atazanavir (I54L), this latter PI being not recommended for HIV-2. 13 Two samples harboured MRV in RT: N69S (n " 1) and S215F (n " 1). Only the S215F mutation confers a possible resistance to zidovudine and stavudine. Finally, one sample harboured MRV in integrase with the T97A mutation, not known to confer on itself resistance to integrase inhibitors.
Thus, at the 1% detection threshold, the prevalence of TDR was 9.8% (95% CI 0.6%-19.0%), 13.2% (95% CI 3.5%-22.9%) and 4.5% (95% CI 0%-17.5%) for PI, NRTI and integrase inhibitor drug classes, respectively.
The median MRV mutational load was 93 copies/mL (IQR 14-1128). Of note, only two MRVs had a mutational load .1000 copies/mL, both present in the same sample.
V3 loop of gp105 UDS
Amplification of the gp105 V3 loop was successful in 19 (40%) samples, with a median of 7503 reads per nucleotide position (range 5536-10 540) obtained by UDS among amplified samples.
Tropism analysis showed that two patients (10.5%) exhibited X4-tropic viruses in .50% of the reads. Among the 17 patients exhibiting a majority of R5-tropic viruses, two (11.8%) displayed a minority of X4-variants (1.5% and 1.9%). Thus, at the 1% threshold, four patients (21%) displayed X4-tropic viruses.
Discussion
In this first study assessing the prevalence of MRV in HIV-2 infection among ART-naive patients, we observed a 2-3-fold higher prevalence of RAM using the 1% detection threshold of mutations, compared with the 20% threshold. Similarly, the proportion of patients with X4-tropic viruses is 2-fold higher using UDS technology.
Our findings in HIV-2 are comparable to that described in ARTnaive HIV-1-infected patients using UDS technology, with a 2-3-fold increase in TDR prevalence. 19, 20 In the present study, MRV were found at low levels, all being below the proportion of 2.5%.
In a previous TDR survey study, conducted in the same cohort using the standard Sanger sequencing during the 2007-11 period, we have shown a TDR prevalence of 5.0% (95% CI 0.1%-9.9%), RAM being detected only in protease, not in RT. 11 In the present study, at the 20% detection threshold, the prevalence of TDR was 7.9%, only in the RT region. Although it concerns different viral genomic regions, no significant evolution of TDR prevalence was observed between the two periods in the ANRS HIV-2 CO5 Cohort. Furthermore, the TDR prevalence observed in this cohort was also in a similar range to that reported in previous studies conducted in the Ivory Coast and Portugal. 12, 13 RAMs found in ART-naive patients in this study were interpreted as possible resistance or resistance to at least one antiretroviral drug in 7 of 11 cases, according to the resistance algorithm. 18 Indeed, the presence of the N69S mutation in RT or T97A in integrase does not in itself lead to resistance.
A limitation concerning the TDR survey in HIV-2 is that no WHO surveillance list of resistance mutations is available for HIV-2, as has been established for HIV-1. 21 Thus, we built a 'home-made' mutations list based on the ARNS resistance algorithm, after having excluded polymorphic drug resistance mutations. 18 In addition, at the time of the study, the 454 technology was the most adapted UDS technology generating sequences of long read length with a sufficiently high coverage to allow assessment of the presence of minority variants and their association on the same viral genome. However, since the end of the present study, this technology has been discontinued by the manufacturer.
A limitation of this study was the low rate of amplification for gp105 and integrase regions; however, this was of a similar range to that described in previous studies conducted by our group regarding HIV-2 tropism. 22 Regarding tropism determination, at the 20% detection threshold, 11% of the ART-naive patients harboured X4-tropic variants, comparable to the 10% and 13% observed in previous HIV-2 studies also conducted in ART-naive patients. 11, 22 In the present study, there is a 2-fold higher proportion of patients harbouring X4-tropic viruses, when X4-minority variants are considered. A similar increase was observed in HIV-1. 23, 24 These first data showing MRV in HIV-2-infected ART-naive patients, added to the stable TDR prevalence at the 20% detection threshold, emphasize the need for pre-therapeutic genotypic resistance tests in patients with detectable VL, as now recommended by the French guidelines. 5 To go further, it would be of interest to assess the impact of MRV on the virological response and to define a mutational load clinical cut-off that compromises virological outcome. However, this type of study will require a large number of patients, which is an issue in HIV-2 clinical trials.
